Publications by authors named "Randy Dockens"

Claim this Profile
P
Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects.
Shan Jing, Yang Lin, Randy Dockens, David Marchisin, Bing He

Dermatol Ther (Heidelb)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects.
Anjaneya Chimalakonda, Shalabh Singhal, Raymond Darbenzio, Randy Dockens, David Marchisin

Clin Pharmacol Drug Dev· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-absorption physicochemical compatibility assessment of 8-drug metabolic cocktail.
Ching Kim Tye, Zhanbin Wang, Randy C Dockens, Blisse Vakkalagadda, Chunlei Wang

Int J Pharm· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.
Vladimir Coric, Stephen Salloway, Christopher H van Dyck, Bruno Dubois, Niels Andreasen, Randy Dockens

JAMA Neurol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.
Charles F Albright, Randy C Dockens, Jere E Meredith, Richard E Olson, Randy Slemmon

J Pharmacol Exp Ther· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Gary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, Shu-Pang Huang, Randy Slemmon, Randy Dockens

Br J Clin Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of oral extended release formulations of 6-hydroxybuspirone.
Sarah J Nicholson, Peter Timmins, Randy C Dockens, Alyson Connor, Robert Croop

Biopharm Drug Dispos· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Vladimir Coric, Christopher H van Dyck, Stephen Salloway, Niels Andreasen, Mark Brody, Randy Dockens

Arch Neurol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men.
Gary Tong, Lorna Castaneda, Jun-Sheng Wang, Oleksandr Sverdlov, Shu-Pang Huang, Randy C Dockens

Clin Drug Investig· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects.
Randy Dockens, Jun-Sheng Wang, Lorna Castaneda, Oleksandr Sverdlov, Shu-Pang Huang

Clin Pharmacokinet· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
Lian Zhou, Randy C Dockens, Peggy Liu-Kreyche, Scott J Grossman, Ramaswamy A Iyer

Drug Metab Dispos· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies.
Huidong Gu, Jian Wang, Anne-Françoise Aubry, Hao Jiang, Jianing Zeng, Randy Dockens

Anal Chem· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Gary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, Shu-Pang Huang, Randy Slemmon, Randy C Dockens

Clin Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.
Vladimir Coric, Howard H Feldman, Dan A Oren, Anantha Shekhar, Joseph Pultz, Randy C Dockens

Depress Anxiety· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?
Seth Sweetser, Michael Camilleri, Sara J Linker Nord, Duane D Burton, Lorna Castenada, Randy Dockens

Am J Physiol Gastrointest Liver Physiol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans.
Mingshe Zhu, Daisy B Whigan, Shu Y Chang, Randy C Dockens

Drug Metab Dispos· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of 6-hydroxybuspirone and its enantiomers administered individually or following buspirone administration in humans.
Randy C Dockens, Anh Q Tran, Jianing Zeng, Robert Croop

Biopharm Drug Dispos· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats.
Harvey Wong, Randy C Dockens, Lori Pajor, Suresh Yeola, James E Grace

Drug Metab Dispos· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range.
Randy C Dockens, Daniel E Salazar, I Edgar Fulmor, Michele Wehling, Mark E Arnold

J Clin Pharmacol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.
John B Kostis, Randy C Dockens, Udho Thadani, Vasnath Bethala, Carl Pepine

Clin Pharmacokinet· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa.
Edyta J Frackiewicz, Stanford S Jhee, Thomas M Shiovitz, Jonathan Webster, Christine Topham, Randy C Dockens

Ann Pharmacother· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis